Search
Close this search box.

Anti-China biotech bills raise alarms at U.S. biotechs

ARTICLE | Politics, Policy & Law

U.S. CEOs worried they could lose access to CDMOs WuXi AppTec and WuXi Biologics

By Steve Usdin, Washington Editor

February 8, 2024 2:59 AM UTC

As a congressional committee prepares for a public hearing in Boston on national security threats posed by Chinese biotech companies, U.S. life sciences CEOs and investors are raising alarms about anti-China legislation.

U.S. biotech executives are contacting members of Congress and trade associations in Washington to express concerns about the Biosecure Act (H.R. 7085) and similar legislation introduced in the Senate, S. 3558. The bills seek to prohibit federal agencies from directly procuring or obtaining equipment or services from biotechs “of concern” or entering into a contract that requires the use of products or services from such companies.